Global Oncology Biomarkers Market Valued at $15.5 Billion in 2022, Expected to Reach $35.2 Billion by 2028 with a CAGR of 14.9%
06 Jul 2023
ASCO
DUBLIN, July 6, 2023 /PRNewswire/ -- The "Oncology Biomarkers: Global Markets" report has been added to
ResearchAndMarkets.com's offering.
The global oncology biomarkers market reached a value of $15.5 billion in 2022 and is anticipated to expand to $35.2 billion by 2028, reflecting a robust compound annual growth rate (CAGR) of 14.9% during the forecast period.
There is a clear shift toward treating cancers based on their tumor genetics rather than their site of origin in the body. The increasing role of biomarkers in clinical diagnostics, precision medicine, and clinical trial management supports growth in this market. Driven by the rising prevalence of cancer, increasing demand in the therapeutic selection and prognosis, precision medicine, and clinical diagnostics, and a growing number of public/private collaborations and government support,
This study provides a comprehensive analysis of oncology biomarkers on a global basis. It aims to offer a range of information, from detailed market analyses within cancer types to overall industry trends, to quantify and qualify the market for products and services in the oncology biomarkers segment. Current and projected market forecasts during the forecast period (2023 to 2028) are discussed. Figures for 2023 are estimated, except where actual results have been reported.
This report includes forecasts by biomarker type, cancer type, application, and region from 2023 through 2028. The report also includes an analysis of leading and emerging competitors in the current worldwide oncology biomarkers market. The competitive environment is examined with a particular focus on how new products and technologies influence the current standard of care.
Companies Mentioned
Abbott
Report Includes
21 data tables and 60 additional tables
An in-depth analysis of the global oncology biomarkers market
Analyses of global market trends, with data from 2020, 2021, 2022, and projections of compound annual growth rates (CAGRs) through 2028
Characterization and quantification of biomarkers market by type, profiling technology, application, cancer type, and region
Discussion on market drivers, challenges and key market strategies and trends
Information on emerging products and technologies, new analytical platforms, novel immunoassays, and bioinformatics tools and discussion on the use of biomarkers in cancer drug development
Profiles of the competitive landscape with an overview of competitor growth strategies and opportunities
Biomarkers allow early disease identification, improved diagnoses, and safer and more efficacious treatments, leading to better patient outcomes and efficient and effective public expenditure on health. Thus, biomarkers are accelerating throughout the cancer care spectrum (screening, diagnosis, prognosis, therapy selection, prediction, response monitoring, and recurrence monitoring) to improve patient care and treatment outcomes.
Also, given the growing burden of cancer on the healthcare ecosystem, there is significant growth in research funding and initiatives to find new clinically relevant biomarkers to understand cancer biology. The discovery of cancer biomarkers is expanding at an unprecedented rate, as previous investments in genomic and proteomic sciences are enabling an improved understanding of disease mechanisms and individual patient responses to therapy. Several cancer biomarkers identified in the past decade are under investigation for their potential applications.
Once these biomarkers are validated and subsequently enter clinical and research applications, the oncology biomarkers market is expected to grow significantly.
Genomic biomarkers are more expensive to assay than protein biomarkers. However, with patients gaining access, oncologists and other providers are becoming more accustomed to incorporating genomic diagnostics into routine care, and the genomic biomarkers market is expected to witness rapid growth in coming years. This market is expected to reach $14.2 billion in 2028, growing at a CAGR of 16.6% through the forecast period.
Key Topics Covered:
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market Outlook
Chapter 4 Market and Technology Background
Overview of Biomarkers
Classification of Biomarkers
Types of Biomarkers
Biomarker Discovery, Verification and Validation
Overview of Cancer
Cancer/Oncology Biomarkers
Oncology Biomarkers Testing Methods
Oncology Biomarkers Testing Types
Biomarker Test Development and Marketing
Chapter 5 Market Dynamics
Drivers
Rising Incidence of Cancer
Increasing Use of Biomarkers in Drug Discovery and Development
Developments in Analytical Technologies and Assay Methods
Increased Availability and Ease of Biomarker Testing
Support from Regulatory Agencies
Barriers
Inadequate Patient Access to and Insurance Coverage of Biomarker Testing
Technical Errors and Delayed Test Results
Low Provider and Patient Awareness
Suboptimal Tissue Procurement and Triaging
Shortages of Laboratories and Personnel
Chapter 6 Market Breakdown by Biomarker Type
Protein Biomarkers
Protein Biomarkers Profiling Technologies
Genomic Biomarker
Genomic Biomarkers Profiling Technologies
Other Biomarkers
Metabolomic Biomarkers
Cellular Biomarkers
Global Market for Oncology Biomarkers, by Biomarker Type
Protein Biomarkers
Genomic Biomarkers
Other Biomarkers
Chapter 7 Market Breakdown by Application
Risk Assessment and Screening
Prognostics
Therapeutic Selection and Clinical Trials
Monitoring
Response Monitoring
Recurrence/Minimal Residual Disease (MRD) Monitoring
Global Market for Oncology Biomarkers by Application
Risk Assessment and Screening
Prognostics
Therapeutic Selection and Clinical Trials
Monitoring
Chapter 8 Market Breakdown by Cancer Type
Market Overview
Melanoma
Others
Global Market for Oncology Biomarkers by Cancer Type
Melanoma
Other Cancers
Chapter 9 Market Breakdown by Region
Chapter 10 Impact of COVID-19
Overview
Implications on Cancer Diagnosis
Implications on Cancer Treatment
Impact on Oncology Biomarkers Market
Chapter 11 Emerging Trends and Technologies in the Market
Emerging Technologies and Trends in the Market
Liquid Biopsy
Circulating Free Nucleic Acids
Circulating Cell-Free DNA (CfDNA)
"Organ Agnostic" Biomarker Testing
Homologous Recombination De?ciency (HRD)
Blood Test for Early-Stage Cancer Detection
Chapter 12 Competitive Landscape
Overview
Mergers and Acquisitions
SWOT Analysis for Global Oncology Biomarker Market
Porter's Five Forces Analysis of Global Oncology Biomarker Market
Chapter 13 Company Profiles
Chapter 14 Appendix: Acronyms
For more information about this report visit https://www.researchandmarkets.com/r/u5hrjc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.